視神經脊髓炎市場：策略性洞察與預測（2026-2035 年）

預計在預測期內，視神經脊髓炎的全球市場將以 7.0% 的複合年成長率成長，從 2026 年的 12 億美元成長到 2035 年的 22 億美元。

針對特定免疫路徑的創新生物製藥的核准，正大幅改變治療格局，為製藥公司創造新的機遇，同時也改善病患的長期預後。

視神經脊髓頻譜疾病（NMOSD）是一種罕見的自體免疫發炎疾病，主要涉及中樞神經系統，尤其是視神經和脊髓。此病以反覆發作的視神經炎和橫貫性脊髓炎為特徵，可能導致失明、癱瘓、慢性神經功能障礙以及生活品質下降。水通道蛋白4（AQP4）抗體的發現從根本上改變了疾病的診斷和治療，使得標靶治療成為可能。隨著我們對此病機制認知的不斷深入，NMOSD市場正迅速從傳統的免疫抑制療法轉向精準生物製藥和新一代免疫療法。

該市場涵蓋已通過核准的療法、新興生物製藥、診斷技術、臨床管理、病患監測、支持性護理和醫療保健服務。孤兒藥監管支持的增加、保險覆蓋範圍的擴大以及不斷成長的創新療法研發管線，持續推動市場的長期成長。

市場促進因素

診斷數量的增加和人們對這種疾病認知的提高

推動市場成長的因素之一是人們對視神經脊髓炎譜系障礙（NMOSD）作為一種獨立的自體免疫神經系統疾病的認知不斷提高。醫生對疾病認知的提高、診斷指南的修訂、AQP4抗體檢測的普及以及先進的磁振造影技術，都顯著提高了診斷準確率，並減少了與多發性硬化症的誤診。

早期診斷可以及時開始治療，降低復發頻率，改善患者的長期預後。

標靶生物製藥的快速普及

近期獲準的標靶生物製藥改變了視神經脊髓炎譜系疾患（NMOSD）的治療模式。補體抑制劑、B細胞清除療法和白細胞介素-6（IL-6）受體抑制劑在預防復發和延緩疾病進展方面均顯示出顯著療效。

隨著這些療法的普及，治療選擇也不斷增加，並且正在各個主要醫療保健系統中推廣應用。

擴大臨床研究和藥物發現

隨著對生物製藥、新一代免疫療法、精準醫療和基於生物標記的治療方法投入的增加，視神經脊髓炎譜系疾病（NMOSD）的治療研發管線不斷擴展。製藥和生技公司正積極開發針對新型免疫通路、以提高療效和安全性的創新療法。

預計臨床試驗活動的活性化將在預測期內帶來更多治療方案的推出。

支持性的法規環境

監管機構持續透過孤兒藥認定、優先審查、快速核准流程和市場獨佔獎勵來促進罕見疾病領域的創新。這些措施降低了研發障礙，並鼓勵對視神經脊髓炎譜系疾病（NMOSD）治療的持續投資。

市場限制因素

先進療法的高成本

由於標靶生技藥品和單株抗體療法價格昂貴，在醫療報銷資源有限的醫療系統中，患者獲得這些療法的機會有限。

患者數量少

NMOSD 是一種罕見的自體免疫疾病，全球患者數量相對較少，導致整體市場規模有限，且在招募臨床試驗受試者方面面臨挑戰。

醫療保健服務取得方面的區域差異

診斷基礎設施、專科醫生資源、保險報銷政策和醫療保健支出方面的差異，持續造成開發中國家市場在獲得治療方面存在差距。

目錄

第1章：執行摘要

• 市場概述
• 主要發現
• 視神經脊髓炎 (NMO) 市場亮點
• 流行病學概述
• 已通過核准療法概述
• 管道和創新亮點
• 市場展望

第2章 疾病與流行病學分析

• 視神經脊髓炎概述
  • 疾病定義
  • 疾病分類
  • 病理學
  • 疾病負擔與臨床影響
• 病因和危險因子
  • 自體免疫機制
  • 遺傳因素
  • 環境因素
• 徵兆和症狀
• 診斷和生物標記
  • 診斷標準
  • 影像技術
  • 血清學生物標記物
    • 水通道蛋白4 (AQP4) 抗體
    • 髓鞘少突膠質細胞糖蛋白（MOG）抗體
• 流行病學分析
  • 視神經脊髓炎的盛行率
  • 視神經脊髓炎的發生率
  • 接受診斷的患者群體
  • 性別分佈
  • 年齡分佈
  • AQP4-IgG陽性NMOSD患者群體
  • AQP4-IgG陰性NMOSD患者群體
  • MOG抗體相關疾病患者族群

第3章 市場動態

• 市場促進因素
  • 診斷率的提高
  • 標靶生技藥品的應用日益廣泛
  • 人們對診斷測試的認知不斷提高，診斷測試的範圍也越來越廣。
• 市場限制因素
  • 高昂的醫療費用
  • 患者數量有限
  • 與還款相關的問題
• 市場機遇
  • 新型作用機制
  • 新興的補體抑制劑
  • 以FcRn為標靶的療法
  • 在新興市場拓展業務
• 波特五力分析
• PESTLE分析

第4章 商業和市場進入

• 市場進入概覽
• 定價分析
• 還款狀態
• 患者支持計劃
• 醫療基礎設施和就醫障礙
• 商業化策略

第5章：創新與通路的現狀

• 創新趨勢
• 按開發階段分類的管道概覽
  • 第一階段
  • 第二階段
  • 第三階段
• 管道分析：按作用機制分析
  • 補體抑制劑
  • 白細胞介素-6 (IL-6) 抑制劑
  • 針對B細胞的療法
  • FcRn抑制劑
  • 其他新型作用機制
• 管道分析：按模式
  • 單株抗體
  • 生物製劑
  • 新型免疫療法
• 臨床試驗現狀
  • 臨床試驗進行中
  • 已完成的臨床試驗
  • 測試結果和主要發現

第6章 當前治療狀況

• 目前治療框架
• 急性癲癇發作的管理
• 維持治療
• 已通過核准療法的分析
  • Soliris（Eculizumab）
  • Ultomiris (Lavrizma)
  • Apprisna（inebilizumab）
  • Ensprin（沙曲珠單抗）
• 治療流程
• 未滿足的醫療需求

第7章 全球視神經脊髓炎市場預測報告：市場規模與預測

• 市場概覽
• 市場規模表現
• 市場預測
• 市場預測：按治療類型分類
• 市場預測：依給藥途徑分類
• 市場預測：按分銷管道分類
• 絕對商機分析

第8章：全球視神經脊髓炎市場預測報告的細分

• 按治療類型
  • IL-6抑制劑
  • 抗CD19療法
  • 其他免疫療法
• 適應症
  • AQP4-IgG陽性視神經脊髓炎譜系疾病
  • AQP4-IgG 陰性視神經脊髓炎譜系疾病
  • MOG抗體相關疾病
• 透過行政途徑
  • 靜脈
  • 口服
  • 其他
• 最終用戶
  • 醫院
  • 專科診所
  • 學術和研究機構
• 透過分銷管道
  • 醫院藥房
  • 零售藥局和專科藥局
  • 網路藥房

第9章 區域分析

• 北美洲
  • 市場規模和成長
  • 需求要素
  • 法規概述
  • 競爭強度
• 歐洲
  • 市場規模和成長
  • 需求促進因素
  • 法規概述
  • 競爭強度
• 亞太地區
  • 市場規模和成長
  • 需求促進因素
  • 法規概述
  • 競爭強度
• 拉丁美洲
  • 市場規模和成長
  • 需求促進因素
  • 法規概述
  • 競爭強度
• 中東和非洲
  • 市場規模和成長
  • 需求促進因素
  • 法規概述
  • 競爭強度

第10章 主要國家分析

• 加拿大
• 德國
• 中國
• 日本
• 印度

第11章 法規與政策概述

• 全球法規環境概述
• 美國法律規範（FDA）
• 歐洲法規結構（EMA）
• 日本的法律規範（PMDA）
• 印度的法規結構（CDSCO）
• 中國的法規結構（NMPA）
• 孤兒藥認定及獎勵
• 定價和兌換政策

第12章 競爭格局

• 市佔率分析
• 競爭基準
• 產品系列比較
• 策略趨勢
  • 新產品發布
  • 夥伴關係與夥伴關係
  • 收購和授權協議
  • 臨床試驗趨勢

第13章：公司簡介

• Alexion Pharmaceuticals
• Amgen
• Roche
• Chugai Pharmaceutical
• Horizon Therapeutics
• Mitsubishi Tanabe Pharma
• Dianthus Therapeutics
• HanAll Biopharma
• AstraZeneca Rare Disease
• Viela Bio

第14章：未來展望

• 新興市場趨勢
• 未來治療模式
• 創新藍圖
• 管道商業化的前景
• 市場成長預測至2035年

第15章：調查方法

• 調查方法
• 初步調查
• 第二次調查
• 數據三角測量
• 預測的前提條件
• 簡稱和定義
• 免責聲明和調查範圍

The Global Neuromyelitis Optica Market is projected to grow at a CAGR of 7.0% during the forecast period, increasing from USD 1.2 billion in 2026 to USD 2.2 billion by 2035.

The approval of innovative biologics targeting specific immune pathways has significantly transformed the treatment landscape, creating new opportunities for pharmaceutical companies while improving long-term patient outcomes.

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune inflammatory disease affecting the central nervous system, particularly the optic nerves and spinal cord. The disease is characterized by recurrent episodes of optic neuritis and transverse myelitis, which can lead to blindness, paralysis, chronic neurological disability, and reduced quality of life. The discovery of aquaporin-4 (AQP4) antibodies has fundamentally changed disease diagnosis and treatment by enabling targeted therapeutic approaches. As understanding of disease mechanisms continues to evolve, the NMOSD market is rapidly transitioning from conventional immunosuppressive therapies toward precision biologics and next-generation immunotherapies.

The market encompasses approved therapies, emerging biologics, diagnostic technologies, clinical management, patient monitoring, supportive care, and healthcare services. Increasing regulatory support for orphan drugs, expanding reimbursement coverage, and a growing pipeline of innovative therapies continue to strengthen long-term market growth.

Market Drivers

Increasing Diagnosis and Disease Awareness

One of the primary drivers of market growth is the increasing recognition of NMOSD as a distinct autoimmune neurological disorder. Improved physician awareness, updated diagnostic guidelines, wider availability of AQP4 antibody testing, and advanced MRI technologies have significantly improved diagnostic accuracy and reduced misdiagnosis with multiple sclerosis.

Earlier diagnosis enables timely treatment initiation, reducing relapse frequency and improving long-term patient outcomes.

Rapid Adoption of Targeted Biologic Therapies

Recent approvals of targeted biologic therapies have transformed the NMOSD treatment landscape. Complement inhibitors, B-cell depletion therapies, and interleukin-6 (IL-6) receptor inhibitors have demonstrated significant efficacy in preventing relapses and slowing disease progression.

The growing availability of these therapies is expanding treatment options and increasing market adoption across major healthcare systems.

Expanding Clinical Research and Drug Development

The NMOSD therapeutic pipeline continues to expand through increasing investments in biologics, next-generation immunotherapies, precision medicine, and biomarker-guided treatment approaches. Pharmaceutical and biotechnology companies are actively developing innovative therapies targeting novel immune pathways to improve efficacy and safety.

Growing clinical trial activity is expected to introduce additional treatment options during the forecast period.

Supportive Regulatory Environment

Regulatory agencies continue to encourage rare disease innovation through orphan drug designation, priority review, accelerated approval pathways, and market exclusivity incentives. These initiatives reduce development barriers and stimulate continued investment in NMOSD therapeutics.

Market Restraints

High Cost of Advanced Therapies

Targeted biologics and monoclonal antibody therapies are associated with substantial treatment costs, limiting patient access in healthcare systems with constrained reimbursement resources.

Limited Patient Population

As a rare autoimmune disease, NMOSD affects a relatively small global patient population, limiting overall market size and creating recruitment challenges for clinical trials.

Regional Disparities in Healthcare Access

Differences in diagnostic infrastructure, specialist availability, reimbursement policies, and healthcare spending continue to create disparities in treatment access across emerging and developing markets.

Technology and Segment Insights

The global NMOSD market can be segmented by therapy type, disease subtype, route of administration, distribution channel, end user, and geography.

By therapy type, the market includes monoclonal antibodies, complement inhibitors, B-cell depletion therapies, IL-6 receptor inhibitors, corticosteroids, immunosuppressive agents, plasma exchange therapies, intravenous immunoglobulins, and supportive treatments. Monoclonal antibodies currently represent the leading therapeutic segment due to their proven effectiveness in relapse prevention and long-term disease management.

By disease subtype, the market includes AQP4 antibody-positive NMOSD, MOG antibody-associated disease, and seronegative NMOSD. AQP4-positive patients account for the largest treated population and remain the primary focus of current biologic therapies.

By route of administration, therapies include intravenous, subcutaneous, and oral formulations. Continued innovation aims to improve treatment convenience through less frequent dosing and alternative administration methods.

By distribution channel, the market includes hospital pharmacies, specialty pharmacies, retail pharmacies, and online pharmacy services.

By end user, the market serves hospitals, specialty neurology centers, academic medical institutions, rehabilitation centers, and ambulatory infusion clinics.

Technological advancements in biomarker discovery, artificial intelligence-assisted diagnostics, genomic medicine, digital patient monitoring, and real-world evidence analytics are improving disease management, treatment personalization, and long-term patient monitoring.

Regional Insights

North America dominates the global NMOSD market owing to advanced healthcare infrastructure, widespread availability of antibody testing, high adoption of biologic therapies, strong reimbursement systems, and active participation in rare disease clinical research. The United States remains the largest individual market for NMOSD therapeutics.

Europe represents another major market supported by comprehensive healthcare systems, increasing access to innovative biologics, favorable orphan drug policies, and growing investment in neurological disease research.

Asia-Pacific is expected to witness the fastest growth during the forecast period due to improving healthcare infrastructure, increasing disease awareness, expanding diagnostic capabilities, rising healthcare expenditure, and growing adoption of advanced therapies across countries including Japan, China, South Korea, and India.

Latin America and the Middle East & Africa are gradually expanding access to NMOSD diagnosis and treatment through healthcare reforms, improved reimbursement programs, and increasing participation in international clinical research.

Competitive Landscape

The NMOSD market is highly competitive, with participation from leading global pharmaceutical companies, biotechnology innovators, and specialized rare disease developers.

Companies are actively investing in biologic therapies, precision medicine platforms, biomarker research, and next-generation immunotherapies to strengthen their market positions. Strategic collaborations, licensing agreements, mergers and acquisitions, and co-development partnerships continue to accelerate innovation and expand global commercialization opportunities.

Competition is increasingly focused on improving relapse prevention, enhancing long-term safety, expanding treatment eligibility, simplifying dosing schedules, and generating robust real-world evidence to support reimbursement and clinical adoption.

Future Outlook

The future NMOSD market is expected to be driven by continued innovation in targeted biologics, personalized medicine, biomarker-guided treatment selection, and advanced immunomodulatory therapies. Emerging technologies such as artificial intelligence, genomic analytics, digital health platforms, and predictive healthcare models are expected to improve diagnosis, optimize treatment strategies, and accelerate drug development.

As additional therapies progress through late-stage clinical development and receive regulatory approvals, the treatment landscape is expected to become increasingly diversified, offering improved efficacy, enhanced safety, broader patient access, and better long-term neurological outcomes.

Conclusion

The global Neuromyelitis Optica market is poised for sustained growth through 2035, supported by increasing disease awareness, expanding diagnosis rates, rapid adoption of targeted biologic therapies, and continuous advances in precision medicine. Although challenges related to high treatment costs, limited patient populations, and reimbursement variability remain, ongoing innovation in immunotherapy, biomarker research, and digital healthcare technologies is expected to reshape the NMOSD treatment landscape. As more innovative therapies enter clinical practice, the market is likely to experience significant improvements in disease management, patient quality of life, and long-term commercial opportunities.

Key Benefits of this Report

• Insightful Analysis: Comprehensive evaluation of market dynamics, treatment landscape, and future growth opportunities.
• Competitive Landscape: Understand key market participants, product portfolios, strategic initiatives, and emerging competitors.
• Market Drivers and Future Trends: Assess technological innovations, regulatory developments, and evolving therapeutic strategies.
• Actionable Recommendations: Support commercialization planning, investment decisions, licensing opportunities, and market entry strategies.
• Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, investors, healthcare providers, researchers, consultants, and policymakers.

What Businesses Use Our Reports For

Market sizing and forecasting, competitive benchmarking, product portfolio evaluation, commercialization planning, licensing and partnership assessments, regulatory strategy development, investment analysis, clinical development planning, and identification of emerging growth opportunities.

Report Coverage

• Historical data from 2021 to 2025, Base year 2025, and Forecast years from 2026 to 2035
• Market analysis by therapy type, disease subtype, route of administration, distribution channel, end user, and geography
• Evaluation of approved therapies, emerging treatments, and clinical development trends
• Competitive intelligence, company profiling, regulatory developments, and strategic partnerships
• Future innovation trends, market opportunities, and long-term industry outlook.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Neuromyelitis Optica (NMO) Market Highlights
• 1.4 Epidemiology Overview
• 1.5 Approved Therapies Overview
• 1.6 Pipeline and Innovation Highlights
• 1.7 Market Outlook (2025-2035)

2. Disease & Epidemiology Analysis

• 2.1 Introduction to Neuromyelitis Optica
  • 2.1.1 Disease Definition
  • 2.1.2 Disease Classification
  • 2.1.3 Pathophysiology
  • 2.1.4 Disease Burden and Clinical Impact
• 2.2 Etiology and Risk Factors
  • 2.2.1 Autoimmune Mechanisms
  • 2.2.2 Genetic Factors
  • 2.2.3 Environmental Factors
• 2.3 Signs and Symptoms
• 2.4 Diagnosis and Biomarkers
  • 2.4.1 Diagnostic Criteria
  • 2.4.2 Imaging Techniques
  • 2.4.3 Serological Biomarkers
    • 2.4.3.1 Aquaporin-4 (AQP4) Antibody
    • 2.4.3.2 Myelin Oligodendrocyte Glycoprotein (MOG) Antibody
• 2.5 Epidemiology Analysis
  • 2.5.1 Prevalence of Neuromyelitis Optica
  • 2.5.2 Incidence of Neuromyelitis Optica
  • 2.5.3 Diagnosed Patient Population
  • 2.5.4 Gender-wise Distribution
  • 2.5.5 Age-wise Distribution
  • 2.5.6 AQP4-IgG Positive NMOSD Population
  • 2.5.7 AQP4-IgG Negative NMOSD Population
  • 2.5.8 MOG Antibody-associated Disease Population

3. Market Dynamics

• 3.1 Market Drivers
  • 3.1.1 Increasing Diagnosis Rates
  • 3.1.2 Growing Adoption of Targeted Biologics
  • 3.1.3 Expanding Awareness and Diagnostic Testing
• 3.2 Market Restraints
  • 3.2.1 High Treatment Costs
  • 3.2.2 Limited Patient Population
  • 3.2.3 Reimbursement Challenges
• 3.3 Market Opportunities
  • 3.3.1 Novel Mechanisms of Action
  • 3.3.2 Emerging Complement Inhibitors
  • 3.3.3 FcRn-targeted Therapies
  • 3.3.4 Expansion in Emerging Markets
• 3.4 Porter's Five Forces Analysis
• 3.5 PESTLE Analysis

4. Commercial & Market Access

• 4.1 Market Access Overview
• 4.2 Pricing Analysis
• 4.3 Reimbursement Landscape
• 4.4 Patient Assistance Programs
• 4.5 Healthcare Infrastructure and Access Barriers
• 4.6 Commercialization Strategies

5. Innovation & Pipeline Landscape

• 5.1 Innovation Trends
• 5.2 Pipeline Overview by Development Stage
  • 5.2.1 Phase I
  • 5.2.2 Phase II
  • 5.2.3 Phase III
• 5.3 Pipeline Analysis by Mechanism of Action
  • 5.3.1 Complement Inhibitors
  • 5.3.2 Interleukin-6 (IL-6) Inhibitors
  • 5.3.3 B-cell Targeted Therapies
  • 5.3.4 FcRn Inhibitors
  • 5.3.5 Other Emerging Mechanisms
• 5.4 Pipeline Analysis by Modality
  • 5.4.1 Monoclonal Antibodies
  • 5.4.2 Biologics
  • 5.4.3 Novel Immunotherapies
• 5.5 Clinical Trial Landscape
  • 5.5.1 Ongoing Trials
  • 5.5.2 Completed Trials
  • 5.5.3 Trial Outcomes and Key Insights

6. Treatment Landscape

• 6.1 Current Treatment Paradigm
• 6.2 Acute Attack Management
• 6.3 Maintenance Therapy
• 6.4 Approved Therapies Analysis
  • 6.4.1 Soliris (eculizumab)
  • 6.4.2 Ultomiris (ravulizumab)
  • 6.4.3 Uplizna (inebilizumab)
  • 6.4.4 Enspryng (satralizumab)
• 6.5 Treatment Algorithm
• 6.6 Unmet Medical Needs

7. Global Neuromyelitis Optica Market Forecast Report Size & Forecast

• 7.1 Market Overview
• 7.2 Historical Market Size (2020-2024)
• 7.3 Market Forecast (2025-2035)
• 7.4 Market Forecast by Therapy Type
• 7.5 Market Forecast by Route of Administration
• 7.6 Market Forecast by Distribution Channel
• 7.7 Absolute Dollar Opportunity Analysis

8. Global Neuromyelitis Optica Market Forecast Report Segmentation

• 8.1 By Therapy Type
  • 8.1.1 IL-6 Inhibitors
  • 8.1.2Anti-CD19 Therapies
  • 8.1.3 Other Immunotherapies
• 8.2 By Indication
  • 8.2.1 AQP4-IgG Positive NMOSD
  • 8.2.2 AQP4-IgG Negative NMOSD
  • 8.2.3 MOG Antibody-associated Disease
• 8.3 By Route of Administration
  • 8.3.1 Intravenous
  • 8.3.2 Oral
  • 8.3.3 Others
• 8.4 By End User
  • 8.4.1 Hospitals
  • 8.4.2 Specialty Clinics
  • 8.4.3 Academic and Research Centers
• 8.5 By Distribution Channel
  • 8.5.1 Hospital Pharmacies
  • 8.5.2 Retail & Specialty Pharmacies
  • 8.5.3 Online Pharmacies

9. Geographical Analysis

• 9.1 North America
  • 9.1.1 Market Size and Growth
  • 9.1.2 Demand Drivers
  • 9.1.3 Regulatory Overview
  • 9.1.4 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size and Growth
  • 9.2.2 Demand Drivers
  • 9.2.3 Regulatory Overview
  • 9.2.4 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Growth
  • 9.3.2 Demand Drivers
  • 9.3.3 Regulatory Overview
  • 9.3.4 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size and Growth
  • 9.4.2 Demand Drivers
  • 9.4.3 Regulatory Overview
  • 9.4.4 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Growth
  • 9.5.2 Demand Drivers
  • 9.5.3 Regulatory Overview
  • 9.5.4 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Overview of Global Regulatory Environment
• 11.2 United States Regulatory Framework (FDA)
• 11.3 European Regulatory Framework (EMA)
• 11.4 Japan Regulatory Framework (PMDA)
• 11.5 India Regulatory Framework (CDSCO)
• 11.6 China Regulatory Framework (NMPA)
• 11.7 Orphan Drug Designation and Incentives
• 11.8 Pricing and Reimbursement Policies

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Product Portfolio Comparison
• 12.4 Strategic Developments
  • 12.4.1 Product Launches
  • 12.4.2 Collaborations and Partnerships
  • 12.4.3 Acquisitions and Licensing Agreements
  • 12.4.4 Clinical Trial Developments

13. Company Profiles

• 13.1 Alexion Pharmaceuticals
  • 13.1.1 Company Overview
  • 13.1.2 Approved Products: Soliris (eculizumab), Ultomiris (ravulizumab)
  • 13.1.3 Key Indications
  • 13.1.4 Pipeline Assets
  • 13.1.5 Strategic Outlook
• 13.2 Amgen
  • 13.2.1 Company Overview
  • 13.2.2 Approved Product: Uplizna (inebilizumab)
  • 13.2.3 Key Indications
  • 13.2.4 Pipeline Assets
  • 13.2.5 Strategic Outlook
• 13.3 Roche
  • 13.3.1 Company Overview
  • 13.3.2 Approved Product: Enspryng (satralizumab)
  • 13.3.3 Key Indications
  • 13.3.4 Pipeline Assets
  • 13.3.5 Strategic Outlook
• 13.4 Chugai Pharmaceutical
  • 13.4.1 Company Overview
  • 13.4.2 Approved Product: Enspryng (satralizumab)
  • 13.4.3 Key Indications
  • 13.4.4 Pipeline Assets
  • 13.4.5 Strategic Outlook
• 13.5 Horizon Therapeutics
  • 13.5.1 Company Overview
  • 13.5.2 Approved Product: Uplizna (inebilizumab)
  • 13.5.3 Key Indications
  • 13.5.4 Pipeline Assets
  • 13.5.5 Strategic Outlook
• 13.6 Mitsubishi Tanabe Pharma
  • 13.6.1 Company Overview
  • 13.6.2 Neurology Portfolio Overview
  • 13.6.3 Key Indications
  • 13.6.4 Pipeline Assets
  • 13.6.5 Strategic Outlook
• 13.7 Dianthus Therapeutics
  • 13.7.1 Company Overview
  • 13.7.2 Pipeline Candidate Portfolio
  • 13.7.3 Mechanism of Action
  • 13.7.4 Clinical Development Status
  • 13.7.5 Strategic Outlook
• 13.8 HanAll Biopharma
  • 13.8.1 Company Overview
  • 13.8.2 Pipeline Candidate Portfolio
  • 13.8.3 Mechanism of Action
  • 13.8.4 Clinical Development Status
  • 13.8.5 Strategic Outlook
• 13.9 AstraZeneca Rare Disease
  • 13.9.1 Company Overview
  • 13.9.2 Approved Products: Soliris (eculizumab), Ultomiris (ravulizumab)
  • 13.9.3 Key Indications
  • 13.9.4 Pipeline Assets
  • 13.9.5 Strategic Outlook
• 13.10 Viela Bio
  • 13.10.1 Company Overview
  • 13.10.2 Approved Product: Uplizna (inebilizumab)
  • 13.10.3 Key Indications
  • 13.10.4 Development History
  • 13.10.5 Strategic Outlook

14. Future Outlook

• 14.1 Emerging Market Trends
• 14.2 Future Treatment Paradigm
• 14.3 Innovation Roadmap
• 14.4 Pipeline Commercialization Outlook
• 14.5 Market Growth Projections Through 2035

15. Methodology

• 15.1 Research Methodology
• 15.2 Primary Research
• 15.3 Secondary Research
• 15.4 Data Triangulation
• 15.5 Forecasting Assumptions
• 15.6 Abbreviations and Definitions
• 15.7 Disclaimer and Scope of Study